Pharma Mar (OTCMKTS:PHMMF) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Pharma Mar (OTCMKTS:PHMMF) from a strong sell rating to a hold rating in a research note published on Wednesday morning, Zacks.com reports.

According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “

Shares of Pharma Mar stock opened at $74.38 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.58 and a quick ratio of 3.44. The business has a fifty day simple moving average of $64.63 and a two-hundred day simple moving average of $79.15. Pharma Mar has a 12 month low of $58.12 and a 12 month high of $145.25.

About Pharma Mar

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs.

Further Reading: Quiet Period Expirations

Get a free copy of the Zacks research report on Pharma Mar (PHMMF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.